The DISCOVER FLOW trial has recently showed an excellent correlation between fractional flow reserve values (FFR) traditionally obtained with coronary CT angiography (CCTA) and the ones obtained with a non invasive technology derived from multi slice computerized tomography (MSCT). Researchers used a novel technology that allows deriving non invasive FFR from MSCT data. Dr. Bon-Kwon...
Review: The CORE-320 multicenter study compared combined angiotomography assessments: anatomical (coronary) and functional (myocardial perfusion) versus anatomical only. For this study, 381 patients who were evaluated by coronary angiography and non-invasive myocardial perfusion gated SPECT were included. In this study the combined evaluation showed better correlation with the observed measurements in assessing the invasive assessment...
Background: Contrast-induced nephropathy has been the subject of many studies not only because of the morbidity associated with prolonged hospital stay, (with dialysis requirement in some cases), but also with an increase in mortality in these patients. The preventive strategy hydration with saline solution 0.9% NaCl is the choice. However, the infusion rate and total...
Insides : 40%-60% of patients with acute coronary syndrome with non ST elevation (ACS) are treated clinically. Prasugrel proved superior to clopidogrel in patients with ACS undergoing invasive treatment (TRITON-TIMI 38). The TRILOGY ACS randomized multicenter trial assessed prasugrel and clopidogrel in patients with ACS treated clinically. Study results were neutral and have already been...
P-selectin is an adhesion molecule involved in the interactions between endothelial cells, platelets and leukocytes. Inclacumab is a recombinant monoclonal antibody against P-selectin, a potential anti-inflammatory, anti-thrombotic and anti-atherogenic. The objective of the SELECT-ACS was to evaluate whether Inclacumab could reduce myocardial damage during percutaneous coronary intervention (PCI) in patients with non-ST elevation myocardial infarction...
The aim of this study was to determine whether patients without ST-segment elevation acute coronary syndromes who were not taking statins previously, can receive high doses of rosuvastatin before coronary angiography or angioplasty and if this action could exert protection in renal function and reduce the incidence of contrast-induced nephropathy (CIN). This prospective study randomized...
It is not clear so far whether pre-hospital fibrinolysis with early angiography could provide a clinical outcome similar to primary percutaneous coronary intervention (PCI) for acute myocardial infarction (AMI). This study included 1,892 patients who presented within three hours of symptom onset and who could not undergo primary angioplasty within the first hour. Patients were...
FFR is the gold standard (Dr. William Fearon) Dr. William reported on the benefits of using FFR: • A high degree of accuracy in identifying lesions that cause ischemia. • It allows you to specify angioplasty safely. • It improves results when compared to standard practice. • It is technically safe, easy to perform, economical...
The objective of this study was to evaluate whether routine use of FFR in all the coronary arteries could change the strategy in stable patients that underwent angiography for the investigation of a chest pain. We included 200 patients with chest pain; for 72 of them, the strategy would be to provide medical treatment by...
The invasive strategy is preferred to treat patients with acute coronary syndromes without ST-segment elevation, but the ideal time for the procedure is controversial. This study randomized 542 patients with acute coronary syndrome without high-risk ST elevation to carry out immediate (invasive treatment within 12 hours) or late treatment (after 48 hours). The primary endpoint...